Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) reports the results of the company's Fifteenth Annual General Meeting (AGM) held on May 7, 2015. The filing confirms that all shareholder resolutions were passed. The document also details the departure of three directors who did not stand for re-election.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes rather than financial performance.
Material Changes and Governance Updates
- Director Departures: Sir Christopher Gent, Tom de Swaan, and Jing Ulrich stepped down from the Board effective at the conclusion of the AGM. They will receive fees for service as directors but no payment for loss of office.
- Shareholder Participation: Total votes cast and withheld represented 75.30% of issued share capital (excluding Treasury Shares), an increase from 74.05% in the 2014 AGM.
- Shareholder Population: The total shareholder population decreased to 137,658 from 140,792 in the prior year.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a procedural report of voting results.
Investor Verification Checklist
- Verify the successful re-election of all standing directors, noting that Resolution 2 (Annual Remuneration Report) received 98.03% support.
- Confirm the specific terms of departure for Sir Christopher Gent, Tom de Swaan, and Jing Ulrich to ensure no unexpected severance payments are made.
- Review the approval of the GSK Share Value Plan (Resolution 24), which passed with 96.72% support.
- Note the authority granted for the company to purchase its own shares (Resolution 21), which passed with 99.84% support.